Pharmaceutical industry Future viability: Swiss pharmaceutical giants get good marks
According to a study by the Lausanne University Institute IMD, the two Swiss pharmaceutical giants Roche and Novartis are among the most future-proof companies in the world. However, the experts see a bleak future for pharmaceutical supplier Lonza and generics manufacturer Sandoz.
25.11.2025, 06:44
SDA
This is the conclusion of the "Future Readiness Indicator" for the year 2025 published on Tuesday, in which the IMD examined the future readiness of companies based on key financial figures, investment activity and innovativeness as well as "soft" factors such as diversity and sustainability.
According to the study, Roche is in second place and Novartis in fourth place in the pharmaceutical sector. According to IMD, the pharmaceutical giants rely on integrated models, i.e. a holistic "ecosystem around healing and health".
The pharmaceutical company Johnson&Johnson, which places even greater emphasis on diversification, research investment and AI, took first place.
In contrast, companies from the pharmaceutical industry that "stick to the old model of pure tablet administration" would be increasingly burdened by expiring patents. According to the IMD, these companies are likely to struggle to keep pace in the future. In particular, the institute mentions the pharmaceutical supplier Lonza and the generics manufacturer Sandoz.
